Table 4.
Correlation between FOXO3 expression and clinicopathological parameters of ESCC patients
| Characteristics | FOXO3 expression status | ||
|---|---|---|---|
| Low (n = 71) | High (n = 32) | P | |
| Gender | |||
| Male | 60 (70.6%) | 25 (29.4%) | 0.430 |
| Female | 11 (61.1%) | 7 (38.9%) | |
| Age | |||
| <60 | 25 (71.4%) | 10 (28.6%) | 0.700 |
| ≥ 60 | 44 (67.7%) | 21 (32.3%) | |
| Tumor size | |||
| < 5 cm | 41 (69.5%) | 18 (30.5%) | 0.899 |
| ≥ 5 cm | 28 (68.3%) | 13 (31.6%) | |
| Tumor stage | |||
| T1+ T2 | 7 (58.3%) | 5 (41.7%) | 0.399 |
| T3+ T4 | 64 (70.3%) | 27 (29.7%) | |
| Histological grade | |||
| Well/moderate | 51 (68.0%) | 24 (32.0%) | 0.738 |
| Poor/NS | 20 (68.9%) | 8 (28.6%) | |
| Lymph node metastasisa | |||
| Negative | 26 (56.5%) | 20 (43.5%) | 0.011 |
| Positive | 44 (80.0%) | 11 (20.0%) | |
| Clinical stagesa | |||
| I + II | 22 (56.4%) | 17 (43.6%) | 0.026 |
| III + IV | 48 (69.3%) | 14 (30.7%) | |
aNumbers do not equal to the total number due to missing data